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high-bleeding-risk surgery (hip/spine surgery and neuro-
surgery), invasive diagnostic testing (lumbar puncture), 
intracranial bleeding (pre-pontine subarachnoid hemor-
rhage and lobar intracerebral hemorrhage) and throm-
bolysis with recombinant tissue plasminogen activator for 
acute ischemic stroke. This case series illustrates the role of 
idarucizumab in improving patient safety in rare emergency 
situations requiring rapid reversal of the anticoagulant 
effect of dabigatran, while highlighting the importance of 
information and education about the availability and appro-
priate use of this recently approved specific reversal agent.
Keywords Direct oral anticoagulants · Non-vitamin 
K antagonist oral anticoagulants · Non-valvular atrial 
fibrillation · Critical bleeding · Emergency procedures · 
Anticoagulation reversal
Abstract Non-vitamin K antagonist oral anticoagulants 
(NOACs) have a favorable benefit-risk profile compared 
with vitamin K antagonists. However, the lack of specific 
reversal agents has made the management of some patients 
receiving long-term treatment with NOACs problematic 
in emergency situations such as major bleeding events or 
urgent procedures. Idarucizumab, a fully humanized Fab 
antibody fragment that binds specifically and with high 
affinity to dabigatran, was recently approved for use in adult 
patients treated with dabigatran when rapid reversal of its 
anticoagulant effect is required. Clinical experience with 
idarucizumab is currently limited. We report 11 real-life 
clinical cases in which idarucizumab was used after mul-
tidisciplinary consultation in a variety of emergency situ-
ations including severe postoperative bleeding, emergency 
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Introduction
Non-vitamin K antagonist oral anticoagulants (NOACs) 
have been developed as direct and specific inhibitors of 
thrombin (dabigatran) or factor Xa (rivaroxaban, apixa-
ban and edoxaban) in order to overcome the limitations 
of vitamin K antagonists [1]. Although NOACs have a 
favorable benefit-risk profile compared with vitamin K 
antagonists [2], and are associated with similar or bet-
ter outcomes in case of major bleeding [3] and urgent 
procedures [4], the lack of specific reversal agents has 
made the management of some patients receiving long-
term treatment with NOACs problematic in rare emer-
gency situations and has been perceived as a barrier to 
the more widespread adoption of NOACs in clinical 
practice [5].
Idarucizumab, a humanized Fab antibody frag-
ment that binds specifically and with high affinity to 
dabigatran [6], has been approved in the United States 
and Europe for use in adult patients treated with dabi-
gatran when rapid reversal of its anticoagulant effect is 
required. The efficacy and safety of idarucizumab (5  g 
administered intravenously as two 2.5-g/50-mL infusions 
or as a bolus injection) in dabigatran-treated patients 
with uncontrollable or life-threatening bleeding and in 
those requiring an urgent surgical or invasive procedure 
are being investigated in RE-VERSE AD, a global phase 
3 prospective cohort study [7]. An interim analysis 
including the first 90 patients enrolled in the study (51 
with serious bleeding and 39 requiring an urgent proce-
dure) reported rapid, complete and sustained reversal of 
the anticoagulant effect of dabigatran following idaruci-
zumab administration [8].
Clinical experience with the use of idarucizumab for 
urgent reversal of the anticoagulant effects of dabigatran 
is currently limited. For the first time, we report 11 cases 
in which idarucizumab was used in emergency situations 
after multidisciplinary consultation in real-life clinical 
practice. These cases were presented and discussed dur-
ing an expert meeting held in Vienna in July 2016. In the 
meantime, two of these cases (No. 1 and No. 11) have 
been reported in separate publications [9, 10]. They are 
included in this series to reflect the variety of clinical 
situations discussed during the expert meeting.
Case series presentation
Selected information on patients’ conditions, indications 
for the use of idarucizumab, coagulation test results and 
clinical outcomes is provided in Table 1.
Case 1: an 83‑year‑old man with excessive bleeding 
after emergency cardiac surgery [9]
An 83-year-old man presented with ascending aortic 
aneurysm complicated by acute aortic syndrome [type 
A intramural hematoma (IMH)], confirmed by computer 
tomography. The condition, in the absence of a surgical 
intervention, is associated with a poor prognosis (moral-
ity rate of 1% per hour during the first 48 h). Transthoracic 
echocardiography identified moderate aortic insufficiency 
and acute exacerbation of chronic kidney disease [estimated 
glomerular filtration rate (eGFR) of 19 mL/min/1.73m²]. 
The patient had non-valvular atrial fibrillation (NVAF) for 
which he was on dabigatran (110 mg b.i.d., last intake on 
the day of admission). Furthermore, he had stage 3 chronic 
kidney disease, arterial hypertension, and a history of right 
hemispheric ischemic stroke, peripheral arterial disease, 
peptic ulcer disease of duodenum and basal cell carcinoma 
resection (face and chest).
Emergency cardiac surgery with cardiopulmonary 
bypass (CPB) and deep hypothermia with temporary cir-
culatory arrest was performed. The dabigatran level [dilute 
thrombin time (dTT)] before surgery was 209 ng/mL. Anti-
coagulation for the intervention was achieved by adminis-
tration of heparin (500 IU/kg) before the onset of CPB and 
monitored using the activated clotting time with a target 
of 400 s during CPB. The supracoronary ascending aortic 
and hemiarch replacement procedure was successfully per-
formed. The aortic cross-clamping time was 64  min, cer-
ebral perfusion time was 34 min and total CPB time was 
195 min. At the end of CPB, anticoagulation was reversed 
by protamine to obtain a normal activated clotting time.
Tranexamic acid was administered in two doses [20 mg/
kg intravenously (i.v.) after sternotomy and 20  mg/kg i.v. 
after the end of CPB). At the end of CPB, the hemoglobin 
level was 8.4 g/dL. A total of 12 units of platelet concen-
trate and 3 units of fresh frozen plasma were administered 
in the operating room. Due to excessive perioperative 
bleeding, idarucizumab (5 g i.v.) was administered follow-
ing CPB cessation. After surgery, the patient was trans-
ferred to the intensive care unit (ICU) for postoperative 
ventilation and extubated after 17 h. The level of dabigatran 
after idarucizumab administration was below 32  ng/mL. 
Three units of packed red blood cells (PRBC) were trans-
fused in the intensive care unit (ICU). Total postoperative 
drainage was 470 mL.
During the postoperative course, the patient required 
diuretic treatment and intensive pulmonary rehabilitation. 
The postoperative course was complicated with pneumonia 
which resolved after antibiotics. Anticoagulation with war-
farin was reinitiated, and on postoperative day 8 the patient 
was discharged to a local hospital for further management. 
On postoperative day 30, the follow-up was uneventful.
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Case 2: a 93‑year‑old woman requiring urgent treatment 
of a periprosthetic femoral hip fracture
After a fall, a 93-year-old woman was admitted to hospi-
tal with a periprosthetic femoral hip fracture and bleeding 
caused by the accident. The patient had previously been 
prescribed dabigatran 110 mg b.i.d. for NVAF and had an 
implanted pacemaker. The laboratory results at admission 
included an activated partial thromboplastin time (aPTT) of 
46 s and a thrombin time (TT) of 225 s. In the next 24 h, 
TT (170 s) did not fall to acceptable values for surgery and 
the patient was transfused 2 units of PRBC due to blood 
loss into her thigh. Taking into consideration a national rec-
ommendation to perform surgery of fractures next to the 
hip within 48 h, the interdisciplinary decision was made to 
perform revision arthroplasty the next day and to adminis-
ter the first vial of idarucizumab (2.5 g i.v.) before the pro-
cedure, which resulted in a TT of 17 s.
Surgery was initiated, and during the operation the 
patient received the second vial of idarucizumab (2.5 g i.v.) 
as well as 1  g of tranexamic acid, 2  g of fibrinogen con-
centrate, 15 µg of desmopressin, 5 units of PRBC (includ-
ing autologous cell salvaged blood) and 2 units of solvent/
detergent plasma. The patient remained under postopera-
tive monitoring in the intensive/intermediate care unit for 
4 days without any complication. On postoperative days 1 
and 2, TT rose again to 129 s and 131 s, respectively, after 
which it fell back to 49 s on day 3. Postoperative thrombo-
prophylaxis was initiated with dalteparin (2 × 5000 IU) on 
day 3. The patient was then transferred to a normal ward, 
where dabigatran was reinitiated by the internist, and then 
to geriatric rehabilitation.
Case 3: a 70‑year‑old man with a comminuted spine 
fracture requiring surgery
A 70-year-old man was admitted with a comminuted spine 
fracture (L1 type A4 and posterior elements of L2). The 
medical history of the patient showed a number of comor-
bidities including NVAF, coronary artery disease, apex 
aneurysm and hyperlipoproteinemia. Among multiple 
medications, the patient was prescribed dabigatran 150 mg 
b.i.d. (he had taken the last dose on the morning of admis-
sion day).
The patient’s condition was assessed as relatively stable. 
After the first laboratory results showed an aPTT of 63.2 s, 
surgery was planned 3 days later to allow time for the elim-
ination of dabigatran. On the day surgery was planned, i.e. 
3 days after dabigatran treatment was discontinued, labo-
ratory tests showed a dTT of 54 ng/mg, a TT of 95 s and 
an aPTT of 44.3  s, and the patient’s condition was wors-
ening. The decision was made to administer idarucizumab 
(5  g i.v.) and the surgical procedure took place without 
complications. Laboratory results after surgery showed a 
dTT of 0 ng/mL, a TT of 15 s and an aPTT of 31.4 s.
Case 4: a 78‑year‑old man with left middle cerebral artery 
occlusion and compensated critical cerebral ischemia 
undergoing emergent extracranial‑intracranial bypass 
surgery
A 78-year-old man was referred to a comprehensive stroke 
center 60 min after displaying an acute onset of left-sided 
weakness and collapsing in public. No obvious neurologi-
cal deficit could be detected. The patient had persistent 
NVAF (treated with dabigatran 150  mg b.i.d.), arterial 
hypertension and a history of deep vein thrombosis.
Multimodal CT scan showed a left middle cere-
bral artery occlusion and compensated critical cerebral 
ischemia, which caused the stroke. Thrombolytic therapy 
was excluded due to the anticoagulant effect of dabigatran 
(laboratory results showed a TT > 120  s and an aPTT of 
47  s). Mechanical thrombectomy could not be performed 
due the kinking of the right common carotid artery and 
stenosis of the right internal carotid artery. A conservative 
approach was rejected due to an extremely high risk of neu-
rological deterioration.
The decision was made to perform emergent extrac-
ranial-intracranial bypass surgery after administration of 
idarucizumab. As the reversal agent was unavailable on 
site, urgent transport was arranged from another hospi-
tal. Ten minutes after the patient was administered 5 g of 
idarucizumab, TT was 17.8  s and the patient was trans-
ferred to the operating room. One hour later, a new blood 
sample showed a TT of 18.4  s and coagulation assessed 
by ROTEM was normal, allowing continuation of the 
procedure.
The surgery was successful without complications and 
the patient was extubated shortly after the procedure. There 
was no complication and no neurological deficit except 
for very mild weakness of acral parts of lower extremities. 
Dabigatran treatment was resumed on postoperative day 7. 
The patient has fully recovered and is able to take care of 
his disabled wife.
Case 5: an 87‑year‑old man with a subdural hematoma 
and a brain hernia requiring neurosurgery
A usually active and healthy 87-year-old man presented to 
the emergency department with general malaise and weak-
ness that had started 5 days before. His condition wors-
ened on the day of admission with sleepiness, occasional 
incoherent speech, confusion and lack of lateralization, as 
well as a tremor of both hands. The chest sounds were nor-
mal; an arrhythmia was found, but no edema. The patient 
was being treated for arterial hypertension and NVAF for 
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which he was prescribed dabigatran 110 mg b.i.d. He had 
no known allergies.
A CT scan revealed a large subdural hematoma and 
brain herniation across the falx and tentorium cerebelli. 
Although the patient was quite active and often rode a bicy-
cle, no obvious evidence of a fall and no external sign of 
trauma was found. After consultation with the neurosur-
geon, surgery was planned the next day.
The laboratory results showed moderate renal impair-
ment reflected by an eGRF of 52 mL/min/1.73 m². The 
presence of dabigatran was confirmed by a dTT of 168 ng/
mL. Approximately 9 h after the last intake of dabigatran 
and 7 h after admission, the patient received a fast i.v. infu-
sion of 5 g idarucizumab, during and after which the condi-
tion of the patient was stable.
The following morning, 15 h after idarucizumab admin-
istration, dTT had decreased to levels under 20 ng/mL. The 
patient was transferred to neurosurgery and trepanation 
was performed. Five days later, the patient was discharged 
home with normal neurological status. Anticoagulation 
therapy was withheld with a recommendation for further 
evaluation before treatment resumption.
Case 6: an 81‑year‑old woman requiring lumbar puncture 
due to a suspicion of neuroinfection
An 81-year-old woman was referred to hospital because of 
somnolence and meningeal symptoms. She was treated for 
NVAF (for which she took dabigatran 110  mg b.i.d.) and 
diabetes mellitus, and she had a history of intracranial hem-
orrhage. Laboratory tests revealed a CRP of 4.4  mg/dL, 
leading to suspicion of a neuroinfection.
A lumbar puncture was urgently needed to confirm 
or rule out the suspected neuroinfection, but the proce-
dure is contraindicated in the presence of anticoagulation 
therapy. As the last intake of dabigatran had taken place in 
the morning and coagulation tests were prolonged, idaru-
cizumab (5 g i.v.) was administered to reverse the antico-
agulation activity of dabigatran. The lumbar puncture was 
performed 30 min later without additional laboratory tests. 
There was no bleeding complication and neuroinfection 
was disproved: the patient actually suffered from an opiate 
intoxication. Dabigatran treatment was reinitiated the next 
day.
Case 7: an 44‑year‑old woman with a pre‑pontine 
subarachnoid hemorrhage
A 44-year-old woman was admitted to hospital due to 
a sudden and violent headache (estimated 10 on Visual 
Analog Scale) with nausea and sickness. She presented 
with meningism but no focal neurological deficit. She was 
treated for hypothyroidism and Conn syndrome, and her 
medical history included a stroke of the right hemisphere 
and a benign liver tumor. She was on dabigatran 150  mg 
b.i.d. for the treatment of deep vein thrombosis, with the 
last intake at 8:00 in the morning on the day of admission.
A CT scan revealed a pre-pontine subarachnoid hemor-
rhage. No specific cause was identified, but the patient was 
fragile and had multiple comorbidities. Laboratory tests 
showed a TT of 73.9 s and an aPTT of 39 s. Idarucizumab 
was not available locally but was obtained from another 
hospital. The patient was administered idarucizumab (5 g 
i.v.) in the late evening, and the following morning the 
TT had decreased to 16.7 s. The patient was discharged 9 
days later after follow-up imaging showed no aneurysm, no 
vasospasm and no evidence of intracerebral hemorrhage.
Case 8: a 78‑year‑old man with aphasia, difficulty 
walking and right faciobrachial hemiparesis undergoing 
thrombolysis for acute ischemic stroke
A 78-year-old man was admitted to hospital in the morn-
ing after his wife noticed aphasia, difficulty walking and 
right faciobrachial hemiparesis. MRI revealed recent-onset 
ischemia and the presence of microbleeds. The patient was 
treated with dabigatran 110 mg b.i.d. for NVAF, with the 
last intake the morning of admission day.
Thrombolysis with recombinant tissue plasminogen 
activator (rt-PA) was indicated. However, laboratory tests 
showed a dTT of 134 ng/mL. It was thus decided to admin-
ister an intravenous bolus injection of idarucizumab (5 g). 
Thrombolysis was performed 20  min later without com-
plications (a reduced dose of rt-PA, 0.6 mg/kg, was used). 
Approximately 30  min after idarucizumab administration, 
the dTT was below 32  ng/mL and remained under this 
detection level during the next 3 days. The patient recov-
ered fully from his stroke and was able to go back to a very 
active way of life.
Case 9: an 88‑year‑old man with spontaneous 
intracerebral hematoma in the right temporo‑parietal lobe
An 88-year-old man with the history of a NVAF taking 
dabigatran 110  mg b.i.d was admitted to the hospital due 
to acute onset of high-graded left-sided hemiparesis. The 
initial NIHSS score was of 10. Cerebral imaging with MRI 
and CT revealed parenchymal hemorrhage in the right 
temporo-parietal lobe. The following laboratory test results 
were obtained: creatinine clearance (Cockcroft-Gault) 61 
mL/min, TT > 150  s and dTT 154 ng/mL. The last intake 
of dabigatran was reported to have taken place 2–4 h prior 
to admission. Acute reversal of the anticoagulation effect 
of dabigatran was performed with 5  g of idarucizumab 
within 35 min after admission. Shortly after administration 
of idarucizumab, dTT decreased below 32 ng/mL and TT 
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below 20 s; the values remained low for 4 consecutive days. 
The size of the intracranial hematoma remained unchanged. 
The patient was transferred to a normal neurological ward 
on day 7 in stable condition.
Case 10: an 84‑year‑old man with right‑sided hemiparesis 
and aphasia undergoing thrombolysis for acute ischemic 
stroke
An 84-year-old male patient was admitted to the stroke unit 
at 11:00 in the morning because of right-sided hemipare-
sis and aphasia. Symptoms had started 3 h prior to admis-
sion. The patient was on dabigatran 110 mg b.i.d. because 
of NVAF. The lower dose regimen had been selected con-
sidering the patient’s age (above 80 years) and his slightly 
elevated serum creatinine level (1.46 mg/dL). The last dab-
igatran dose had been taken on the morning of admission.
The initial NIHSS score was 9 and cerebral CT was 
normal, providing an ASPECTS score of 10. An ischemic 
stroke involving the basal ganglia and the cella media was 
diagnosed. Laboratory tests showed a dabigatran level of 
79 ng/mL and a TT of 129 s. As no other contraindications 
to thrombolysis with rt-PA were identified, idarucizumab 
(5 g) as an intravenous infusion was administered to reverse 
the anticoagulant effects of dabigatran.
After administration of idarucizumab, a blood sample 
was taken and thrombolysis with the standard dose of rt-PA 
was immediately initiated. Laboratory tests showed a dabi-
gatran level below 20 ng/mL and a TT of 16 s. Thromboly-
sis was successfully completed. Treatment with dabigatran 
110 mg b.i.d. was restarted on day 2. The patient’s condi-
tion improved and on day 9 he was admitted to a rehabilita-
tion unit with an NIHSS score of 4.
Case 11: a 68‑year‑old man with undergoing thrombolysis 
for a right‑sided homonymous hemianopsia [10]
A 68-year-old man present at hospital after a sudden onset 
of visual disturbances, dizziness and slight headache. Neu-
rological examination 25  min later revealed right-sided 
homonymous hemianopsia and marginal evidence of non-
fluent aphasia from a stroke 20 months earlier. Brain MRI 
revealed restricted diffusion on diffusion-weighted imaging 
in the medial part of the left occipital lobe without demar-
cation in FLAIR.
The patient’s medical history included recurrent tran-
sient ischemic attacks. He had been taking dabigatran 
110 mg b.i.d. for NVAF. At the time of treatment initiation, 
his renal function was slightly impaired; however, the pre-
scribed dose regimen may have been inappropriate given 
the patient’s age and medical history. Laboratory examina-
tions revealed an eGFR of 102 mL/min, a dTT of 34 ng/
mL and an aPTT of 34 s. It was decided to neutralize the 
anticoagulant activity of dabigatran and to perform throm-
bolysis with rt-PA, considering hemianopsia as a function-
ally relevant deficit (mRS of 3).
The patient received a rapid i.v infusion of idarucizumab 
(5  g), which was followed, after 10  min (and a total of 
110 min from symptom onset), by intravenous thromboly-
sis with rt-PA (70  mg). Transcranial Doppler sonography 
shortly after rt-PA infusion showed regular blood flow in 
both posterior cerebral arteries. Transthoracic echocardiog-
raphy on day 2 did not reveal cardiac thrombi or structural 
heart disease. The patient was discharged on day 3 with 
slightly improved hemianopsia (NIHSS 3, mRS 2). Dabi-
gatran treatment was resumed at the higher dosage (150 mg 
b.i.d.) as renal function tests were normal.
Discussion
We report 11 real-life clinical cases in which idarucizumab 
was used after multidisciplinary consultation in a variety of 
emergency situations requiring rapid reversal of the antico-
agulant effect of dabigatran. The indication for long-term 
anticoagulation was NVAF in 10 patients and deep vein 
thrombosis in 1 patient. Emergency situations included 
severe postoperative bleeding in 1 case, emergency high-
bleeding-risk surgery (hip/spine surgery and neurosurgery) 
in 4 cases, invasive diagnostic testing (lumbar puncture) in 
1 case, intracranial bleeding (pre-pontine subarachnoid and 
lobar intracerebral hemorrhage) in 2 cases and the deci-
sion to perform thrombolysis with rt-PA in 3 cases. Before 
administration of idarucizumab, laboratory coagulation 
tests were performed in all cases and the dTT was used to 
calculate the dabigatran concentration in 5 cases.
Clinical situations requiring urgent reversal of the anti-
coagulant effect of NOACs are expected to be relatively 
rare. Due to the short half-lives of NOACs, especially when 
renal function is normal, restoration of hemostasis can be 
expected within 12–24  h after the last dose intake [11]. 
The incidence of major bleeding events is significantly 
reduced with NOACs compared with vitamin K antago-
nists [12], and treatment discontinuation (along with sup-
portive measures) may often be sufficient even in patients 
with moderate-to-severe bleeding [11, 13]. If an emergency 
surgical intervention or invasive procedure is required, it 
may in some cases be possible to postpone it until at least 
12 h (and ideally 24 h) after the last NOAC dose intake to 
reduce the risk of bleeding complications [11].
However, there are situations such as life-threatening 
bleeding or urgent interventions when discontinuation of 
the NOAC treatment is insufficient to address the clini-
cal need, particularly among patients with renal impair-
ment [14]. Guidelines from the International Society on 
Haemostasis and Thrombosis lists the following potential 
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indications for the use of specific reversal agents or anti-
dotes: life-threatening bleeding, bleeding into a critical 
organ or closed space, prolonged bleeding despite local 
hemostatic measures, high risk of recurrent bleeding 
because of overdose or delayed clearance of the drug, 
and the need for an urgent intervention associated with a 
high risk of bleeding [15]. As some patients with NVAF 
present with acute ischemic stroke despite well-managed 
anticoagulation (1.5 per year in recent clinical trials accord-
ing to Kirchhof et  al. [16]) or due to treatment underdos-
ing, thrombolysis with rt-PA may be urgently required in a 
NOAC-treated patient.
The clinical experience reported in this case series con-
firms the efficacy and ease of use of idarucizumab, and 
illustrates its role in improving patient safety in a variety 
of emergency situations requiring rapid reversal of the anti-
coagulant effect of dabigatran. The development and dis-
semination of institution-specific anticoagulation reversal 
protocols by multidisciplinary teams are needed to ensure 
timely and appropriate use of this new therapeutic option. 
Availability of a specific reversal agent is an important fac-
tor to be taken into consideration when choosing an antico-
agulant in clinical practice.
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